Bank of New York Mellon Corp Makes New Investment in Personalis, Inc. $PSNL

Key Points

• Bank of New York Mellon acquired 189,065 Personalis shares worth approximately $2.53 million, giving it about a 0.18% stake. Institutional investors and hedge funds collectively own 61.91% of the company.
• Personalis shares opened at $17.20, near their 52-week high of $18.89, despite continued losses. The company missed quarterly EPS estimates at a loss of $0.30 per share, although revenue of $22.36 million exceeded expectations.
• Analyst sentiment is mixed and has recently weakened, with an average “Hold” rating and a consensus price target of $14.54. Insiders also sold 256,233 shares worth roughly $3.57 million over the past three months.

Bank of New York Mellon Corp bought a new position in Personalis, Inc. (NASDAQ:PSNL - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 189,065 shares of the company's stock, valued at approximately $2,533,000. Bank of New York Mellon Corp owned approximately 0.18% of Personalis at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock valued at $27,000 after purchasing an additional 1,479 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Personalis during the 4th quarter valued at $31,000. Legal & General Group Plc purchased a new position in shares of Personalis during the 2nd quarter valued at $30,000. BNP Paribas Financial Markets increased its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of Personalis in the fourth quarter worth $82,000. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Price Performance

Shares of PSNL opened at $17.20 on Tuesday. The company has a market capitalization of $1.80 billion, a PE ratio of -15.78 and a beta of 2.31. Personalis, Inc. has a one year low of $4.95 and a one year high of $18.89. The company's fifty day moving average price is $14.61 and its 200 day moving average price is $10.36.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.04). The firm had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. Analysts anticipate that Personalis, Inc. will post -1.07 earnings per share for the current year.

Insider Activity at Personalis

In other news, CFO Aaron Tachibana sold 4,982 shares of the company's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the transaction, the chief financial officer owned 198,833 shares of the company's stock, valued at approximately $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares of the company's stock, valued at approximately $3,558,668.88. The trade was a 29.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 256,233 shares of company stock valued at $3,568,236 over the last three months. 4.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PSNL. Needham & Company LLC cut Personalis from a "buy" rating to a "hold" rating in a research report on Monday, July 20th. Morgan Stanley upped their target price on Personalis from $9.00 to $13.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 9th. Zacks Research downgraded Personalis from a "hold" rating to a "strong sell" rating in a research note on Tuesday, July 21st. Craig Hallum lowered Personalis from a "buy" rating to a "hold" rating and set a $16.25 price target for the company. in a report on Monday, August 24th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Personalis in a report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $14.54.

Personalis Company Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.